Intermittent cyclophosphamide with prednisone versus placebo for polyneuropathy with IgM monoclonal gammopathy

Neurology

Volumn 69, Issue 1, 2007, Pages 50-59

  Niermeijer, J M F ^a   Eurelings, M ^a   Van Der Linden, M W ^b   Lokhorst, H M ^b   Franssen, H ^b   Fischer, K ^b   Teunissen, L L ^c   Van Den Berg, L H ^a   Schobben, F ^b   Wokke, J H J ^a   Notermans, N C ^a  

^a UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^b UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^c ST ANTONIUS HOSPITAL   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOPHOSPHAMIDE; DEXAMETHASONE; IMMUNOGLOBULIN M; M PROTEIN; PLACEBO; PREDNISONE;

ADULT; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; ELECTROMYOGRAM; FEMALE; FOLLOW UP; HUMAN; MALE; MEDIAN NERVE; MONOCLONAL IMMUNOGLOBULINEMIA; MULTIPLE CYCLE TREATMENT; MUSCLE STRENGTH; NAUSEA; NERVE CONDUCTION; POLYNEUROPATHY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RANKIN SCALE; RIVERMEAD MOBILITY INDEX; SCORING SYSTEM; SENSATION; SENSORY ANALYSIS; SHORT FORM 36; STRATIFICATION; TREATMENT DURATION; TREATMENT OUTCOME;

ACTIVITIES OF DAILY LIVING; AGED; CROSS-OVER STUDIES; CYCLOPHOSPHAMIDE; DEXAMETHASONE; DISEASE PROGRESSION; DOUBLE-BLIND METHOD; DRUG ADMINISTRATION SCHEDULE; DRUG THERAPY, COMBINATION; ELECTROMYOGRAPHY; FEMALE; FOLLOW-UP STUDIES; HUMANS; IMMUNOGLOBULIN M; MALE; MIDDLE AGED; MUSCLE STRENGTH; PARAPROTEINEMIAS; POLYNEUROPATHIES; PREDNISONE; QUALITY OF LIFE; SENSATION; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

EID: 34347406705     PISSN: 00283878     EISSN: None     Source Type: Journal    
DOI: 10.1212/01.wnl.0000265055.28218.cc     Document Type: Article

References (38)

1. Tatum AH. Experimental paraprotein neuropathy, demyelination by passive transfer of human-IgM anti-myelin-associated glycoprotein. Ann Neurol 1993;33:502-506.
2. Hays AP, Lee SS, Latov N. Immune reactive C3d on the surface of myelin sheaths in neuropathy. J Neuroimmunol 1988;18:231-244.
3. Leibowitz S, Gregson NA, Kennedy M, Kahn SN. IgM paraproteins with immunological specificity for a Schwann cell component and peripheral nerve myelin in patients with polyneuropathy. J Neurol Sci 1983;59:153-165.
4. Van den Berg LH, Hays AP, Nobile-Orazio E, et al. Anti-MAG and anti-SGPG antibodies in neuropathy. Muscle Nerve 1996;19:637-643.
5. van den Berg LH, Lankamp CL, De Jager AE, et al. Anti-sulphatide antibodies in peripheral neuropathy. J Neurol Neurosurg Psychiatry 1993;56:1164-1168.
6. Takatsu M, Hays AP, Latov N, et al. Immunofluorescence study of patients with neuropathy and IgM M proteins. Ann Neurol 1985;18:173-181.
7. Mendell JR, Sahenk Z, Whitaker JN, et al. Polyneuropathy and IgM monoclonal gammopathy: studies on the pathogenetic role of anti-myelin- associated glycoprotein antibody. Ann Neurol 1985;17:243-254.
8. Pestronk A, Li F, Griffin J, et al. Polyneuropathy syndromes associated with serum antibodies to sulfatide and myelin-associated glycoprotein. Neurology 1991;41:357-362.
9. Nobile-Orazio E, Manfredini E, Carpo M, et al. Frequency and clinical correlates of anti-neural IgM antibodies in neuropathy associated with IgM monoclonal gammopathy. Ann Neurol 1994;36:416-424.
10. Trojaborg W, Galassi G, Hays AP, Lovelace RE, Alkaitis M, Latov N. Electrophysiologic study of experimental demyelination induced by serum of patients with IgM M proteins and neuropathy. Neurology 1989;39:1581-1586.
11. Lunn MPT, Crawford TO, Hughes RAC, Griffin JW, Sheikh KA. Anti-myelin-associated glycoprotein antibodies alter neurofilament spacing. Brain 2002;125:904-911.
12. Lunn MP, Nobile-Orazio E. Immunotherapy for IgM anti-Myelin-Associated Glycoprotein paraprotein-associated peripheral neuropathies. Cochrane Database Syst Rev 2003;1:CD002827.
13. Notermans NC, Lokhorst HM, Franssen H, et al. Intermittent cyclophosphamide and prednisone treatment of polyneuropathy associated with monoclonal gammopathy of undetermined significance. Neurology 1996;47:1227-1233.
14. Gorson KC. Clinical features, evaluation, and treatment of patients with polyneuropathy associated with monoclonal gammopathy of undetermined significance (MGUS). J Clin Apheresis 1999;14:149-153.
15. Miller AB, Hoogstraten B, Staquet M, Winkler A. Reporting results of cancer treatment. Cancer 1981;47:207-214.
16. Lennon S, Johnson L. The modified Rivermead Mobility Index: validity and reliability. Disabil Rehabil 2000;22:833-839.
17. Bamford JM, Sandercock PA, Warlow CP, Slattery J. Interobserver agreement for the assessment of handicap in stroke patients. Stroke 1989;20:828.
18. Smith IS. The natural history of chronic demyelinating neuropathy associated with benign IgM paraproteinaemia. A clinical and neurophysiological study. Brain 1994;117:949-957.
19. Notermans NC, van Dijk GW, Van der GY, van Gijn J, Wokke JH. Measuring ataxia: quantification based on the standard neurological examination. J Neurol Neurosurg Psychiatry 1994;57:22-26.
20. Merkies IS, Schmitz PI, van der Meche FG, Samijn JP, Van Doorn PA. Quality of life complements traditional outcome measures in immune-mediated polyneuropathies. Neurology 2002;59:84-91.
21. Aaronson NK, Muller M, Cohen PD, et al. Translation, validation, and norming of the Dutch language version of the SF-36 Health Survey in community and chronic disease populations. J Clin Epidemiol 1998;51:1055-1068.
22. Eurelings M, Lokhorst HM, Kalmijn S, Wokke JH, Notermans NC. Malignant transformation in polyneuropathy associated with monoclonal gammopathy. Neurology 2005;64:2079-2084.
23. Notermans NC, Franssen H, Wieneke GH, Wokke JH. Temperature dependence of nerve conduction and EMG in neuropathy associated with gammopathy. Muscle Nerve 1994;17:516-522.
24. Notermans NC, Franssen H, Eurelings M, Van der GY, Wokke JH. Diagnostic criteria for demyelinating polyneuropathy associated with monoclonal gammopathy. Muscle Nerve 2000;23:73-79.
25. Dyck PJ, Litchy WJ, Kratz KM, et al. A plasma exchange versus immune globulin infusion trial in chronic inflammatory demyelinating polyradiculoneuropathy. Ann Neurol 1994;36:838-845.
26. Kaku DA, England JD, Sumner AJ. Distal accentuation of conduction slowing in polyneuropathy associated with antibodies to myelin-associated glycoprotein and sulphated glucuronyl paragloboside. Brain 1994;117:941-947.
27. Bril V, Ellison R, Ngo M, Bergstrom B, Raynard D, Gin H. Electrophysiological monitoring in clinical trials. Roche Neuropathy Study Group. Muscle Nerve 1998;21:1368-1373.
28. Grobbee DE, Hoes AW. Confounding and indication for treatment in evaluation of drug treatment for hypertension. BMJ 1997;315:1151-1154.
29. Molenaar DS, Vermeulen M, de Haan R. Reliability and validity of disability measures in peripheral neuropathies. 1-1-1999. Abstract. Presented at the Peripheral Nerve Society; 1999.
30. Molenaar DS, Van Doorn PA, Vermeulen M. Pulsed high dose dexamethasone treatment in chronic inflammatory demyelinating polyneuropathy: a pilot study. J Neurol Neurosurg Psychiatry 1997;62:388-390.
31. Merkies IS, Lauria G. 131st ENMC international workshop: Selection of outcome measures for peripheral neuropathy clinical trials. 10-12 December 2004, Naarden, The Netherlands. Neuromuscul Disord 2006;16:149-156.
32. Perry MC, Yarbro JW, eds. Second malignancies associated with chemotherapy. 479-506. 1-1-1984. Toxicity of chemotherapy. New York: Grune and Stratton; 1984.
33. Comi G, Roveri L, Swan A, et al. A randomised controlled trial of intravenous immunoglobulin in IgM paraprotein associated demyelinating neuropathy. J Neurol 2002;249:1370-1377.
34. Pestronk A, Florence J, Miller T, Choksi R, Al Lozi MT, Levine TD. Treatment of IgM antibody associated polyneuropathies using rituximab. J Neurol Neurosurg Psychiatry 2003;74:485-489.
35. Renaud S, Gregor M, Fuhr P, et al. Rituximab in the treatment of polyneuropathy associated with anti-MAG antibodies. Muscle Nerve 2003;27:611-615.
36. Renaud S, Fuhr P, Gregor M, et al. High-dose rituximab and anti-MAG-associated polyneuropathy. Neurology 2006;66:742-744.
37. Sherman WH, Latov N, Lange D, Hays R, Younger D. Fludarabine for IgM antibody-mediated neuropathies. Ann Neurol 1994;36:326-327.
38. Blume G, Pestronk A, Goodnough LT. Anti-Mag antibody-associated polyneuropathies: improvement following immunotherapy with monthly plasma-exchange and IV-cyclophosphamide. Neurology 1995;45:1577-1580.